These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 92978)

  • 1. [Excretion of urinary hydroxyproline in urinary tract diseases].
    Guarino A; Comar OB; Taccone W; Cicalese V
    Arch Sci Med (Torino); 1979; 136(2):249-54. PubMed ID: 92978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Use of urinary hydroxyproline excretion as a marker of bone metastases in prostatic cancer (1)].
    Kurokawa K; Imai K; Yamanaka H; Tomaru Y; Kitaura K
    Hinyokika Kiyo; 1985 Dec; 31(12):2119-25. PubMed ID: 2421558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Urinary hydroxyproline excretion as a marker of bone metastasis in prostatic cancer].
    Rinsho K
    Nihon Hinyokika Gakkai Zasshi; 1983 Jan; 74(1):76-80. PubMed ID: 6191064
    [No Abstract]   [Full Text] [Related]  

  • 4. [Cholesterol and urinary tract diseases].
    Frick J; Spiteller G
    Z Urol Nephrol; 1968 Dec; 61(12):833-8. PubMed ID: 4183283
    [No Abstract]   [Full Text] [Related]  

  • 5. On the origin of lactic dehydrogenase isoenzymes in urine.
    Dubach UC
    Helv Med Acta; 1966 Jun; 33(2):139-50. PubMed ID: 4164323
    [No Abstract]   [Full Text] [Related]  

  • 6. [Use of urinary hydroxyproline elimination in the detection of bone metastases secondary to prostatic carcinoma].
    de la Peña J; Cárcamo P; Martínez ME; Martínez-Piñeiro JA
    Actas Urol Esp; 1983; 7(3):199-204. PubMed ID: 6624563
    [No Abstract]   [Full Text] [Related]  

  • 7. Use of urinary hydroxyproline excretion as a tumor marker in diagnosis and follow-up of prostatic carcinoma.
    Unni Mooppan MM; Kim H; Wang JC; Tobin MS; Wax SH
    Prostate; 1983; 4(4):397-405. PubMed ID: 6191318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Collagen cross-link metabolites in urine as markers of bone metastases in prostatic carcinoma.
    Miyamoto KK; McSherry SA; Robins SP; Besterman JM; Mohler JL
    J Urol; 1994 Apr; 151(4):909-13. PubMed ID: 7510346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary tissue factor levels in patients with bladder and prostate cancer.
    Lwaleed BA; Francis JL; Chisholm M
    Eur J Surg Oncol; 2000 Feb; 26(1):44-9. PubMed ID: 10718179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydroxyproline excretion in malignant neoplastic disease.
    Hosley HF; Taft EG; Olson KB; Gates S; Beebe RT
    Arch Intern Med; 1966 Dec; 118(6):565-71. PubMed ID: 5925444
    [No Abstract]   [Full Text] [Related]  

  • 11. Urinary hydroxyproline excretion as a marker of bone metastasis in prostatic cancer.
    Rinsho K; Aoyagi K
    Tohoku J Exp Med; 1982 Aug; 137(4):461-2. PubMed ID: 7123546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical significance of cholesterol excretion in the urine].
    Jüngst D; Osterholzer M; Lazik E; Karl HJ
    Acta Med Austriaca Suppl; 1979; 6():406-9. PubMed ID: 299242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone alkaline phosphatase isoenzyme and urinary hydroxyproline in healthy subjects, patients with osteolytic metastases, and patients with primary hyperparathyroidism.
    Stĕpán JJ; Mikulecký M; Bek V; Broulík P; Pacovský V
    Neoplasma; 1989; 36(4):495-501. PubMed ID: 2770935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of nuclear matrix protein-22 as a clinical diagnostic marker for bladder cancer.
    Chang YH; Wu CH; Lee YL; Huang PH; Kao YL; Shiau MY
    Urology; 2004 Oct; 64(4):687-92. PubMed ID: 15491702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Urinary hydroxyproline excretion before and after hypophysectomy in patients with bone metastases from breast cancer].
    Ditzel J; Jordal R; Riskoer N
    Ugeskr Laeger; 1968 Oct; 130(42):1766-71. PubMed ID: 5724711
    [No Abstract]   [Full Text] [Related]  

  • 16. Postabsorptive urinary hydroxyproline test in patients with metastatic bone disease from breast cancer.
    Niell HB; Palmieri GM; Neely CL; McDonald MW
    Arch Intern Med; 1981 Oct; 141(11):1471-3. PubMed ID: 7283558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Urinary hydroxyproline in advanced breast carcinoma and response to treatment with medroxyprogesterone acetate (MAP) in high doses].
    Martoni A; Pedelini G; Colalongo G; Biagi R; Mambelli M; Jafelice G; Rocchetta G; Piana E; Pannuti F
    Minerva Med; 1980 Sep; 71(31):2215-9. PubMed ID: 7422143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hydroxyprolinuria in relation to bone metastases in patients with breast cancer].
    Rico Lenza H; Millán Núñez-Cortés J; Rodríguez Mora VI; Espinós Pérez D
    Rev Esp Oncol; 1980; 27(1):61-6. PubMed ID: 7209108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Study of hydroxyproline excretion in patients with prostatic cancer.
    Romics I; Budavári I; Kisbenedek L; Balogh F
    Int Urol Nephrol; 1981; 13(3):275-8. PubMed ID: 7327902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Total, dialyzable, and nondialyzable postabsorptive hydroxyproline. Values in patients with cancer.
    Niell HB; Palmieri GM; Neely CL; Maxwell TA; Hopkins SC; Soloway MS
    Arch Intern Med; 1983 Oct; 143(10):1925-7. PubMed ID: 6625779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.